- Home
- BCYC vs EVMN Comparison
BCYC vs EVMN Comparison
Compare BCYC & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCYC | EVMN |
|---|---|---|
| Founded | 2009 | 2020 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.8M | 241.3M |
| IPO Year | 2019 | 2025 |
Fundamental Metrics
Financial Performance| Metric | BCYC | EVMN |
|---|---|---|
| Price | $3.89 | $6.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 11 |
| Target Price | $9.50 | ★ $24.13 |
| AVG Volume (30 Days) | 542.9K | ★ 762.1K |
| Earning Date | 10-29-2026 | 11-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.23 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $13,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 85.71 |
| 52 Week Low | $3.55 | $6.02 |
| 52 Week High | $9.08 | $33.20 |
Technical Indicators
Market Signals| Indicator | BCYC | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 19.52 |
| Support Level | $3.81 | N/A |
| Resistance Level | $3.95 | $13.35 |
| Average True Range (ATR) | 0.19 | 0.53 |
| MACD | 0.04 | -0.09 |
| Stochastic Oscillator | 78.32 | 5.72 |
Price Performance
Historical ComparisonAbout BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.